<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03200015</url>
  </required_header>
  <id_info>
    <org_study_id>HE16-00019</org_study_id>
    <nct_id>NCT03200015</nct_id>
  </id_info>
  <brief_title>Rituximab, Cyclophosphamide, Vincristine and Prednisone (R-CHOP) Plus Metformin in Diffuse Large-B-cell Lymphoma</brief_title>
  <official_title>Effect of Metformin in Combination With R-CHOP for the First Line Treatment of Patients With Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Dr. Jose E. Gonzalez</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitario Dr. Jose E. Gonzalez</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the safety and effectiveness of metformin as an adjunct to RCHOP chemotherapy
      for patients with newly diagnosed diffuse large-B cell lymphoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with newly diagnosed diffuse large-B cell non Hodgkin lymphoma, irrespective of cell
      of origin status will receive metformin in combination to Rituximab, cyclophosphamide,
      doxorubicin, vincristine and prednisone (RCHOP) chemotherapy for 6 cycles, until response
      evaluation as reported elsewhere:

      1.- Rituximab 375 mg/m2 IV, day 1. 2.- Cyclophosphamide 750 mg/m2 IV, day 1. 3.- Doxorubicin
      50 mg/m2 IV day 1. 4.- Vincristine 1.4 mg/m2 IV (2 mg maximum dose). 5.- Prednisone 60 mg/m2
      PO days 1-5. Six cycles every 21 days.

      Metformin will be added and administered in an outpatient basis, starting with 425 mg twice a
      day for 1 week, followed by 850 mg twice a day for 1 week, and lastly 850 mg every 8 hours
      maximum dose until re-staging. Laboratory tests will be performed serially.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rates</measure>
    <time_frame>6 months</time_frame>
    <description>Overall, partial and complete responses to chemoimmunotherapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>Survival with freedom from progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>Survival from diagnosis until death or last follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>2-5 years</time_frame>
    <description>Survival from diagnosis until death or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression or relapse</measure>
    <time_frame>2-5 years</time_frame>
    <description>Time from diagnosis until disease progression or relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Metformin arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin 850 mg tablets. Initial dose 425 mg twice a day for 1 week, followed by 850 mg twice a day for 1 week, titrated to a maximum dose 850 mg every 8 hours until disease response evaluation study date (Computed tomography or positron emission tomography)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms</description>
    <arm_group_label>Metformin arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly diagnosed nodal diffuse large-B cell non Hodgkin lymphoma
             according to the 2008 World Health Organization classification for lymphoid
             malignancies

          -  No previous treatment other than prednisone or equivalent glucocorticoid up to 60
             mg/m2 for 14 days

          -  Good performance status (Eastern Cooperative Oncology Group scale 0-2)

          -  Life expectancy &gt;6 months

          -  Independently of the diagnosis of diabetes mellitus (any type)

        Exclusion Criteria:

          -  History of intolerance or hypersensitivity reactions to metformin

          -  Primary central nervous system lymphoma

          -  History of other previous malignant neoplastic diseases &lt;5 years prior to enrollment

          -  Evidence of systemic infection at the time of study

          -  HIV, hepatitis C or B virus infection

          -  Aspartate transaminase or alanine transaminase &gt;2x upper limit of normal, bilirubin
             &gt;2.5 times upper limit of normal

          -  Serum creatinine &gt;1.5 mg/dL or chronic renal disease

          -  Cardiac insufficiency (New York Heart Association scale &gt;1 or ejection fraction &lt;50%)

          -  History of transformation from an indolent lymphoma

          -  Pregnancy

          -  History of lactic acidosis or alcoholism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Gómez-Almaguer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Universitario Dr. José Eleuterio González</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>César H Gutiérrez-Aguirre, MD</last_name>
    <phone>+528183486136</phone>
    <email>hematohu@yahoo.com.mx</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andres Gómez-De León, MD</last_name>
    <phone>+528183486136</phone>
    <email>drgomezdeleon@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario Dr. José Eleuterio González</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64610</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Gómez-De Leon, MD</last_name>
      <phone>+528183486136</phone>
      <email>drgomezdeleon@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.gov/ct2/show/record/NCT02531308</url>
    <description>Similar study registered in Clinical trials.gov</description>
  </link>
  <reference>
    <citation>Asensio-López MC, Lax A, Pascual-Figal DA, Valdés M, Sánchez-Más J. Metformin protects against doxorubicin-induced cardiotoxicity: involvement of the adiponectin cardiac system. Free Radic Biol Med. 2011 Nov 15;51(10):1861-71. doi: 10.1016/j.freeradbiomed.2011.08.015. Epub 2011 Aug 25.</citation>
    <PMID>21907790</PMID>
  </reference>
  <reference>
    <citation>Shi WY, Xiao D, Wang L, Dong LH, Yan ZX, Shen ZX, Chen SJ, Chen Y, Zhao WL. Therapeutic metformin/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012 Mar 1;3:e275. doi: 10.1038/cddis.2012.13.</citation>
    <PMID>22378068</PMID>
  </reference>
  <reference>
    <citation>Alkhatib Y, Abdel Rahman Z, Kuriakose P. Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study. Leuk Lymphoma. 2017 May;58(5):1130-1134. doi: 10.1080/10428194.2016.1239822. Epub 2016 Oct 5.</citation>
    <PMID>27701994</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2017</study_first_posted>
  <last_update_submitted>May 10, 2018</last_update_submitted>
  <last_update_submitted_qc>May 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitario Dr. Jose E. Gonzalez</investigator_affiliation>
    <investigator_full_name>David Gomez Almaguer</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No plans for a sharing plan pre-determined</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

